Handelsbanken Fonder AB Increases Position in IDEXX Laboratories, Inc. $IDXX

Handelsbanken Fonder AB increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,344 shares of the company’s stock after acquiring an additional 2,150 shares during the quarter. Handelsbanken Fonder AB’s holdings in IDEXX Laboratories were worth $20,186,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Elyxium Wealth LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $3,666,459,000. J. Stern & Co. LLP boosted its stake in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after buying an additional 2,642,200 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after buying an additional 1,442,174 shares during the last quarter. Wellington Management Group LLP grew its position in shares of IDEXX Laboratories by 318.1% during the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after buying an additional 592,834 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth $332,265,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on IDXX. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Barclays reduced their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, UBS Group lifted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Stock Performance

IDXX stock opened at $570.58 on Thursday. The stock’s 50 day simple moving average is $561.22 and its 200 day simple moving average is $582.62. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The firm has a market cap of $44.95 billion, a P/E ratio of 40.13, a P/E/G ratio of 3.13 and a beta of 1.54. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the company posted $3.50 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.